These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 26960983)
1. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983 [TBL] [Abstract][Full Text] [Related]
2. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma. Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282 [TBL] [Abstract][Full Text] [Related]
3. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899 [TBL] [Abstract][Full Text] [Related]
4. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493 [TBL] [Abstract][Full Text] [Related]
5. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795 [No Abstract] [Full Text] [Related]
6. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224 [TBL] [Abstract][Full Text] [Related]
7. Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli. Li XY; Zhou LF; Gao LJ; Wei Y; Xu SF; Chen FY; Huang WJ; Tan WF; Ye YP Cancer Lett; 2018 Apr; 420():195-207. PubMed ID: 29425683 [TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E1 Inhibits Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475 [TBL] [Abstract][Full Text] [Related]
9. AT-101 inhibits hedgehog pathway activity and cancer growth. Wang J; Peng Y; Liu Y; Yang J; Huang M; Tan W Cancer Chemother Pharmacol; 2015 Sep; 76(3):461-9. PubMed ID: 26113054 [TBL] [Abstract][Full Text] [Related]
10. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism. Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254 [TBL] [Abstract][Full Text] [Related]
11. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened. Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710 [TBL] [Abstract][Full Text] [Related]
13. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740 [TBL] [Abstract][Full Text] [Related]
14. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003 [TBL] [Abstract][Full Text] [Related]
15. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance. Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107 [TBL] [Abstract][Full Text] [Related]
16. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163 [TBL] [Abstract][Full Text] [Related]
17. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591 [TBL] [Abstract][Full Text] [Related]